Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 12% Improvement Relative Risk Mortality (b) 57% c19hcq.com Hernandez-Cardenas et al. HCQ RCT LATE TREATMENT Favors HCQ Favors control
Hernandez-Cardenas, 214 patient HCQ late treatment RCT: 12% lower mortality [p=0.66] https://c19p.org/hernandezcardenas
copied to clipboard
Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: a randomized controlled trial
Hernandez-Cardenas et al., medRxiv, doi:10.1101/2021.02.01.21250371 (Preprint)
5 Feb 2021    Source   PDF   Share   Tweet
Very late stage RCT with 214 patients, mean SpO2 65%, 162 on mechanical ventilation, showing no significant difference in mortality.
Patients not intubated at baseline show greater improvement, HR 0.43 [0.09-2.03].
Table 4 shows different results to the abstract - table 4 adjusted HR 0.80 [0.51-1.23], abstract HR 0.88 [0.51-1.53]. There was no significant difference in severe adverse events.
risk of death, 12.0% lower, RR 0.88, p = 0.66, treatment 106, control 108.
risk of death, 57.0% lower, RR 0.43, p = 0.29, subgroup not intubated at baseline.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hernandez-Cardenas et al., 5 Feb 2021, Randomized Controlled Trial, Mexico, preprint, 6 authors, average treatment delay 7.4 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit